The investing outlet weighs how much rides on Viking's lead obesity drug candidate when projecting what a $1,000 stake could become.
Recap by typeshit. Full story at The Motley Fool on MSN.
A general explainer on how GLP-1 receptor agonists affect blood sugar and appetite, with advice on support while taking them.
A sponsored-style look at compounded tirzepatide and semaglutide through telehealth firm Mochi Health, noting compounded drugs aren't FDA approved for safety or quality.
Among the items: Walmart plans free GLP-1 diabetes drugs for employees in 2027, and Verdiva Bio dropped a phase II oral GLP-1 study citing market changes.
Longevity Technology reports BodySpec's new offering targets GLP-1 users worried about muscle, with body scans said to take about 12 minutes.
Reuters looks at influencers pushing dietary supplements to people on weight loss drugs, turning TikTok into a sales engine for so-called GLP-1 products.
GoodRx says approved peptides went through safety and effectiveness testing, while wellness peptides sold without approval lack that evidence and carry risks.
Loading…